This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fults, D. Articles by Cawthon, R. M. Search for Related Content PubMed PubMed Citation Articles by Fults, D. Articles by Cawthon, R. M.

p53 Mutation and Loss of Heterozygosity on Chromosomes 17 and 10 during Human Astrocytoma Progression¹

Division of Neurosurgery [D. F., D. B., M. W. T., C. A. P.] and Department of Human Genetics [R. M. C.], Howard Hughes Medical Institute, University of Utah School of Medicine, Salt Lake City, Utah 84132

The human brain tumor, astrocytoma, typically progresses through three histopathologically defined stages with the passage of time: one premalignant stage, low-grade astrocytoma; and two malignant stages, anaplastic astrocytoma and glioblastoma multiforme. We correlated the results of a sequence analysis of the tumor suppressor gene, p53, and a restriction fragment length polymorphism analysis of chromosomes 17 and 10 in 45 patients with cerebral astrocytomas at different stages. To detect p53 mutations in tumor DNA, we analyzed polymerase chain reaction products corresponding to every p53-coding exon for single-strand conformation polymorphisms and confirmed the mutations by sequencing. Loss of heterozygosity (LOH) was determined by Southern transfer analysis of somatic and tumor DNA from these same patients using polymorphic markers for various loci on chromosomes 10 and 17. p53 mutations were found in 7 of 25 glioblastomas (28%), in 5 of 14 anaplastic astrocytomas (36%) but in 0 of 6 low-grade astrocytomas. p53 mutations were found in 62% of patients with LOH on chromosome 17p. These results indicated that p53 inactivation is a common genetic event in astrocytoma progression that may signal the transition from benign to malignant tumor stages. LOH on chromosome 10 was found in 61% of glioblastomas, in 23% of anaplastic astrocytomas, but in 0% of low-grade astrocytomas. LOH on chromosome 10 and p53 mutation were found together only in patients with glioblastoma multiforme (22%), suggesting that these genetic changes may accumulate during astrocytoma progression.

¹ This work was supported by Grant 1R29CA52855 from the National Cancer Institute (to D.F.).

² To whom requests for reprints should be addressed, at Division of Neurosurgery, University of Utah School of Medicine, 50 North Medical Drive, Salt Lake City, UT 84132.

Received 8/23/91. Accepted 11/12/91.

This article has been cited by other articles:

				K. M. Reilly, R. G. Tuskan, E. Christy, D. A. Loisel, J. Ledger, R. T. Bronson, C. D. Smith, S. Tsang, D. J. Munroe, and T. Jacks Susceptibility to astrocytoma in mice mutant for Nf1 and Trp53 is linked to chromosome 11 and subject to epigenetic effects PNAS, August 31, 2004; 101(35): 13008 - 13013. [Abstract] [Full Text] [PDF]

				C. Gomez-Manzano, W.K. A. Yung, R. Alemany, and J. Fueyo Genetically modified adenoviruses against gliomas: From bench to bedside Neurology, August 10, 2004; 63(3): 418 - 426. [Abstract] [Full Text] [PDF]

				I. F. Pollack, S. D. Finkelstein, J. Woods, J. Burnham, E. J. Holmes, R. L. Hamilton, A. J. Yates, J. M. Boyett, J. L. Finlay, R. Sposto, et al. Expression of p53 and Prognosis in Children with Malignant Gliomas N. Engl. J. Med., February 7, 2002; 346(6): 420 - 427. [Abstract] [Full Text] [PDF]

				K. Ueki, R. Nishikawa, Y. Nakazato, T. Hirose, J. Hirato, N. Funada, T. Fujimaki, S. Hojo, O. Kubo, T. Ide, et al. Correlation of Histology and Molecular Genetic Analysis of 1p, 19q, 10q, TP53, EGFR, CDK4, and CDKN2A in 91 Astrocytic and Oligodendroglial Tumors Clin. Cancer Res., January 1, 2002; 8(1): 196 - 201. [Abstract] [Full Text] [PDF]

				I. F. Pollack, S. D. Finkelstein, J. Burnham, E. J. Holmes, R. L. Hamilton, A. J. Yates, J. L. Finlay, and R. Sposto Age and TP53 Mutation Frequency in Childhood Malignant Gliomas: Results in a Multi-institutional Cohort Cancer Res., October 1, 2001; 61(20): 7404 - 7407. [Abstract] [Full Text] [PDF]

				J. A. Cerrato, W.K. A. Yung, and T.-J. Liu Introduction of mutant p53 into a wild-type p53-expressing glioma cell line confers sensitivity to Ad-p53-induced apoptosis Neuro-oncol, April 1, 2001; 3(2): 113 - 122. [Abstract] [PDF]

				A. J. Janss, A. Maity, C.-B. Tang, R. J. Muschel, W. G. McKenna, L. Sutton, and P. C. Phillips Decreased cyclin B1 expression contributes to G2 delay in human brain tumor cells after treatment with camptothecin Neuro-oncol, January 1, 2001; 3(1): 11 - 21. [Abstract] [PDF]

				B. U. Bender, M. Gutsche, S. Gläsker, B. Müller, G. Kirste, C. Eng, and H. P. H. Neumann Differential Genetic Alterations in von Hippel-Lindau Syndrome-Associated and Sporadic Pheochromocytomas J. Clin. Endocrinol. Metab., December 1, 2000; 85(12): 4568 - 4574. [Abstract] [Full Text]

				H. Kato, S. Kato, T. Kumabe, Y. Sonoda, T. Yoshimoto, S. Kato, S.-Y. Han, T. Suzuki, H. Shibata, R. Kanamaru, et al. Functional Evaluation of p53 and PTEN Gene Mutations in Gliomas Clin. Cancer Res., October 1, 2000; 6(10): 3937 - 3943. [Abstract] [Full Text]

				M. Tenan, G. Fulci, M. Albertoni, A.-C. Diserens, M.-F. Hamou, M. El Atifi-Borel, J.-J. Feige, M. S. Pepper, and E. G. Van Meir Thrombospondin-1 Is Downregulated by Anoxia and Suppresses Tumorigenicity of Human Glioblastoma Cells J. Exp. Med., May 15, 2000; 191(10): 1789 - 1798. [Abstract] [Full Text] [PDF]

				C. Raffel, L. Frederick, J. R. O'Fallon, P. Atherton-Skaff, A. Perry, R. B. Jenkins, and C. D. James Analysis of Oncogene and Tumor Suppressor Gene Alterations in Pediatric Malignant Astrocytomas Reveals Reduced Survival for Patients with PTEN Mutations Clin. Cancer Res., December 1, 1999; 5(12): 4085 - 4090. [Abstract] [Full Text] [PDF]

				H. Fujisawa, M. Kurrer, R. M. Reis, Y. Yonekawa, P. Kleihues, and H. Ohgaki Acquisition of the Glioblastoma Phenotype during Astrocytoma Progression Is Associated with Loss of Heterozygosity on 10q25-qter Am. J. Pathol., August 1, 1999; 155(2): 387 - 394. [Abstract] [Full Text] [PDF]

				E. C. Wooten, D. Fults, R. Duggirala, K. Williams, A. P. Kyritsis, M. L. Bondy, V. A. Levin, and P. O'Connell A study of loss of heterozygosity at 70 loci in anaplastic astrocytoma and glioblastoma multiforme with implications for tumor evolution Neuro-oncol, July 1, 1999; 1(3): 169 - 176. [Abstract] [PDF]

				C. Mejia, A. Pellin, S. Navarro, V. Castel, and A. Llombart-Bosch A New Mutation of the p53 Gene in Human Neuroblastoma, Not Correlated with N-myc Amplification International Journal of Surgical Pathology, July 1, 1999; 7(3): 149 - 154. [Abstract] [PDF]

				M. Nozaki, M. Tada, H. Kobayashi, C.-L. Zhang, Y. Sawamura, H. Abe, N. Ishii, and E. G. Van Meir Roles of the functional loss of p53 and other genes in astrocytoma tumorigenesis and progression Neuro-oncol, April 1, 1999; 1(2): 124 - 137. [Abstract] [PDF]

				H. Li, M. Alonso-Vanegas, M. A. Colicos, S. S. Jung, H. Lochmuller, A. F. Sadikot, G. J. Snipes, P. Seth, G. Karpati, and J. Nalbantoglu Intracerebral Adenovirus-mediated p53 Tumor Suppressor Gene Therapy for Experimental Human Glioma Clin. Cancer Res., March 1, 1999; 5(3): 637 - 642. [Abstract] [Full Text] [PDF]

				R. B. Ray, R. Steele, K. Meyer, and R. Ray Transcriptional Repression of p53 Promoter by Hepatitis C Virus Core Protein J. Biol. Chem., April 25, 1997; 272(17): 10983 - 10986. [Abstract] [Full Text] [PDF]

				H.-K. Ng, M. Phil, K.-W. Lo, D. P. Huang, and W.-S. Poon p53 in Low-grade Gliomas International Journal of Surgical Pathology, January 1, 1994; 1(3): 163 - 170. [Abstract] [PDF]